SNTI
Senti Biosciences Inc.

2,625
Loading...
Loading...
News
all
press releases
Senti Biosciences Skyrockets 400% On Oversubscribed PIPE Deal, Promising Cancer Trial Data: Retail Overjoyed
The stock rallied to levels last seen in April 2023, drawing significant attention from retail investors.
Stocktwits·10mo ago
News Placeholder
More News
News Placeholder
Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition Companies
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of investors in the following Special Purpose Acquisition Companies (SPAC). The stock prices...
Globe Newswire·1y ago
News Placeholder
SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips SNTI stock results show that Senti Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023. The post SNTI...
InvestorPlace·2y ago
News Placeholder
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 Cash and anticipated...
Globe Newswire·2y ago
News Placeholder
Short Interest in Senti Biosciences, Inc. (NASDAQ:SNTI) Decreases By 21.9%
Senti Biosciences, Inc. (NASDAQ:SNTI Get Free Report) saw a large drop in short interest in the month of February. As of February 29th, there was short interest totalling 269,900 shares, a...
Ticker Report·2y ago
News Placeholder
Head to Head Review: Senti Biosciences (NASDAQ:SNTI) versus ZIVO Bioscience (NASDAQ:ZIVO)
Senti Biosciences (NASDAQ:SNTI Get Free Report) and ZIVO Bioscience (NASDAQ:ZIVO Get Free Report) are both small-cap medical companies, but which is the better investment? We will...
Zolmax·2y ago
News Placeholder
Senti Biosciences (NASDAQ:SNTI) & X4 Pharmaceuticals (NASDAQ:XFOR) Head to Head Analysis
Senti Biosciences (NASDAQ:SNTI Get Free Report) and X4 Pharmaceuticals (NASDAQ:XFOR Get Free Report) are both small-cap medical companies, but which is the better business? We will...
Zolmax·2y ago
News Placeholder
Senti Biosciences to reduce workforce by 37%
Senti Biosciences to reduce workforce by 37...
SeekingAlpha.com: All News·2y ago
News Placeholder
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024...
Globe Newswire·2y ago

Latest SNTI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.